Other Operating Income: 6.32----Total Income From Operations: 390.21: 410.55: 449.64: EXPENDITURE ...

Indoco Remedies' share price rose after the company received final USFDA approval for its ANDA to market Allopurinol tablets ...

Indoco Remedies board of directors has proposed a final dividend of ₹0.20 per equity share of face value of ₹2 each ...

Following the earnings announcement, shares of Indoco Remedies saw sharp fall. The stock fell over 12% from its day’s high of ...

Mumbai: Indoco Remedies Ltd. has announced the final approval of Allopurinol Tablets USP 200 mg through its Abbreviated New ...

Quarterly Net Loss at Rs. 26.24 crore in March 2025 down 169.86% from Rs. 37.56 crore in March 2024. EBITDA stands at Rs.

Indoco Remedies rose 1.28% to Rs 245.80 after the company announced that it has received final approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug ...

Indoco Remedies receives US FDA final approval to market allopurinol tablets USP 200 mg: Our Bureau, Mumbai Friday, May 23, 2025, 12:30 Hrs [IST] Indoco Remedies Ltd., a fully int ...

Our Bureau, New Delhi Friday, May 23, 2025, 10:30 Hrs [IST] Indoco Remedies has reported a net loss of Rs. 41.34 crore ...

Traders will monitor IndusInd Bank Ltd., InterGlobe Aviation Ltd., Oil and Natural Gas Corp., and Ircon International Ltd.

As the brand looks further to strengthen its footprint in the oral sensitivity segment, FCB Ulka will lead Sensodent's ...